Publications
Print PDF
Stephen Hahn Should Focus on Stability in First Days As US FDA Commissioner, Stakeholders Say
December 18, 2019
Derrick Gingery
Pink Sheet

Axinn partner Chad Landmon was quoted in the Pink Sheet article, "Stephen Hahn Should Focus on Stability in First Days As US FDA Commissioner, Stakeholders Say."

Click here to access the article. A subscription is required.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.